Clovis Oncology Inc.
BOULDER, Colorado, June 2, 2011 -
- PF-01367338 is currently in Phase 1/2 development in combination with
chemotherapy in patients with solid tumors
- Phase 2 data from IV formulation demonstrate encouraging activity and
safety profile
- Clovis to assume responsibility for all development and commercial
activities worldwide
- Pfizer to invest in Clovis Oncology
Clovis Oncology, Inc.
